Azitra, a clinical-stage biopharmaceutical company, announced it will present data on ATR-COSF, a topical recombinant filaggrin protein aimed at reducing wrinkles and improving skin elasticity, at the BIO-Europe conference. Early ex vivo studies showed a 56% wrinkle reduction and improved skin elasticity, supporting progression to a first-in-human trial with initial results expected by the end of 2026. The company also updated on ATR-04, a live biotherapeutic for cancer treatment-related rashes, expanding its trial to include more patient groups. These developments highlight Azitra's innovative approach to dermatology, combining microbial engineering and protein technology for skincare and therapeutic applications.
Azitra, Inc. is advancing dermatological treatments with promising early data on ATR-COSF showing a 56% reduction in wrinkles in ex vivo human skin models. For readers following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 19:42 WIB: out of 150 priced US health stocks, 83 rose and 55 fell. Notable movers include Sana Biotechnology Inc (SANA) at USD 2.42 with 95% buy order activity, Cassava Sciences Inc (FLNA) at USD 0.50 with 88% sell order activity, and BioNano Genomics Inc (BNGO) at USD 1.18 with 100% sell order activity and a typical hold time of 53 days.
project44 has partnered with Snowflake to enhance supply chain decision-making through Mo, an AI-powered supply chain analyst. Mo uses project44's extensive logistics data and Snowflake Cortex AI to provide accurate, consistent answers to complex sup...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
